Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630756 · ClinicalTrials.gov registry record · Phase 1
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
A Phase 1 study of Advanced Haematological Malignancies, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT04630756: Completed Phase 1 study of Advanced Haematological Malignancies, sponsored by AstraZeneca.
NCT04630756 is a Phase 1 study of Advanced Haematological Malignancies that has completed, run by AstraZeneca. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 17 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04630756, a Phase 1 study of Advanced Haematological Malignancies, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.
Primary Outcome
Safety and tolerability of AZD4573 in combination with acalabrutinib was assessed.
Conditions Studied
Interventions
- DRUG Acalabrutinib
- DRUG AZD4573
Study Locations (17)
Other
- Research Site - Clayton
- Research Site - Nedlands
- Research Site - Lille
- Research Site - Dublin
- Research Site - Galway
- Research Site - Krakow
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Palma de Mallorca
- Research Site - Plymouth
California
- Research Site - Duarte
- Research Site - La Jolla
Texas
- Research Site - Houston
Utah
- Research Site - Salt Lake City
Quebec
- Research Site - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-02-17 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
What the finished NCT04630756 record still lists
NCT04630756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Advanced Haematological Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib is the first listed.
NCT04630756 lists 17 locations in 5 states (Other, California, Texas).
Frequently Asked Questions
What is clinical trial NCT04630756 about?
NCT04630756 is a clinical study titled "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer". This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematologi...
What is the current status of trial NCT04630756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-02-17. Estimated completion is 2025-02-27.
What conditions does trial NCT04630756 study?
This clinical trial studies the following conditions: Advanced Haematological Malignancies.
What interventions are being tested in trial NCT04630756?
The interventions under investigation include: Acalabrutinib (DRUG), AZD4573 (DRUG).
Who is sponsoring clinical trial NCT04630756?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04630756 being conducted?
This trial has 17 study locations across California, Texas, Utah, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04630756's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI